Impacto cardiovascular, conducta diagnóstica y terapéutica del feocromocitoma como causa de hipertensión arterial.
Resumen
INTRODUCCIÓN. Los feocromocitomas son tumores que provienen de las células neuroendócrinas de la médula adrenal y producen alta secreción de catecolaminas. Generan complicaciones cardiovasculares graves que suelen asociarse con crisis hipertensivas. Es importante valorar el impacto cardiovascular de esta entidad. OBJETIVO. Realizar una revisión exhaustiva de las diversas manifestaciones de los feocromocitomas como causa de hipertensión arterial, su impacto cardiovascular, conducta diagnóstica y terapéutica. MATERIALES Y MÉTODOS. Revisión bibliográfica y análisis de 141 artículos científicos que incluyeron temas sobre el impacto cardiovascular, conducta diagnóstica y terapéutica del feocromocitoma como causa de hipertensión arterial. Se usó bases de datos: Medline, Embase, Scopus, Pubmed, Google Académico. Criterios de búsqueda en DECS, MeSH: “pheochromocytoma OR hypertension arterial AND cardiomyopathy”, en inglés- español. Fueron seleccionados: 13 publicaciones de texto completo, 10 artículos retrospectivos, 2 guías de práctica clínica y 1 revisión. Se excluyeron 128 artículos científicos. RESULTADOS. Se realizó una revisión de las manifestaciones clínicas de los feocromocitomas como causa de hipertensión arterial y el impacto cardiovascular se relacionó con la producción de catecolaminas. Para el diagnóstico, la sensibilidad de la resonancia magnética es del 93-100%; la especificidad de resonancia magnética o tomografía computarizada en combinación con gammagrafía con metayodobencilguanidina con 123I es cercana al 100%. La resección del feocromocitoma tiene potencial curativo. CONCLUSIÓN. Los feocromocitomas presentan variabilidad clínica, se asocian a complicaciones cardiovasculares y cerebrovasculares graves por producción de catecolaminas. El diagnóstico oportuno y eficaz debe realizarse mediante resonancia magnética y gammagrafía en caso de alta sospecha clínica. El tratamiento quirúrgico es de elección.
Descargas
Citas
Kim JY et al. Recent updated on grading and classification of neuroendocrine tumors. Annals of diagnostic pathology 2017; 29:11-36. Y Tang L. et al. Practica Approach to the Clasification of WHO Grade 3 (G3) Ell diferrentionated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol 2016; 40:1192-1202.8. [Tabla Modificada: Clasificación OMS para tumors neuroendocrinos Gastroenteropancreáticos (GEP-NETs)].
Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(6):1915–42. Available from: https://academic.oup.com/jcem/article/99/6/1915/2537399
Herbert Chen MD, Rebecca S. Sippel MD, Karel Pacak, M.D. PD. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma & Medullary Thyroid Cancer. Pancreas. 2010;39(6):775–83. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419007/
Aygun N. Pheochromocytoma and paraganglioma: from epidemiology to clinical findings. SiSli Etfal Hastan Tip Bul / Med Bull Sisli Hosp. 2020;54(2):159–68. Available from: https://pubmed.ncbi.nlm.nih.gov/32617052/
Tziomalos K. Secondary Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):11. Available from: https://pubmed.ncbi.nlm.nih.gov/31038070/
Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: Data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61. Available from: https://pubmed.ncbi.nlm.nih.gov/19497985/
Wang L, Li N, Yao X, Chang G, Zhang D, Heizhati M, et al. Detection of Secondary Causes and Coexisting Diseases in Hypertensive Patients: OSA and PA Are the Common Causes Associated with Hypertension. Hindawi BioMed Res Int. 2017;2017. Avialable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485286/
Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: A study of 94 cases from a single center. Endocr Connect. 2018;7(1):186–92. Available from:https://pubmed.ncbi.nlm.nih.gov/29217652/
Van Berkel A, Lenders JWM, Timmers HJLM. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170(3). https://eje.bioscientifica.com/view/journals/eje/170/3/R109.xml
Neumann H, Young W. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552–65. Available from: https://pubmed.ncbi.nlm.nih.gov/31390501/
Zelinka T, Petrák O, Turková H, Holaj R, Štrauch B, Kršek M, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res. 2012;44(5):379–84. Available from:https://pubmed.ncbi.nlm.nih.gov/22517556/
Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB, et al. Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction. J Am Coll Cardiol. 2016 May 24;67(20):2364–74. Available from:https://pubmed.ncbi.nlm.nih.gov/27199060/
Aygun N. Pheochromocytoma and paraganglioma: from treatment to follow-up. SiSli Etfal Hastan Tip Bul / Med Bull Sisli Hosp. 2020;54(4):391–8. Available from:https://pubmed.ncbi.nlm.nih.gov/33364876/
Azadeh N, Ramakrishna H, Bhatia NL, Charles JC, Mookadam F. Therapeutic goals in patients with pheochromocytoma: a guide to perioperative management. Ir J Med Sci. 2016;185(1):43–9. Available from:https://pubmed.ncbi.nlm.nih.gov/26650752/
Patel D, Phay JE, Yen TWF, Dickson P V., Wang TS, Garcia R, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27(5):1329–37. Available from:https://pubmed.ncbi.nlm.nih.gov/32112212/
Lenders WML, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005. Aug 20-26; 336(9486): 665-75: DOI: 10.1016/S0140-6736(05)67139-5 .
Pappachan JM, Tun NN, Arunagirinathan G, Sodi R, Hanna FWF. Pheochromocytomas and Hypertension. Curr Hypertens Rep. 2018;20(1):3. Available from: https://pubmed.ncbi.nlm.nih.gov/29356966/
Iglesias P, Santacruz E, García-Sancho P, Marengo AP, Guerrero-Pérez F, Pian H, et al. Pheochromocytoma: A three-decade clinical experience in a multicenter study. Rev Clin Esp [Internet]. 2020;(xx):10–7. DOI: https://doi.org/10.1016/j.rce.2019.12.016
Sohail S, Shafiq W, Raza SA, Zahid A, Mir K, Azmat U. Clinical Characteristics and Outcome of Patients With Pheochromocytoma: A Single Center Tertiary Care Experience. Cureus. 2020;12(5):6–12. Available from: https://www.cureus.com/articles/29967-clinical-characteristics-and-outcome-of-patients-with-pheochromocytoma-a-single-center-tertiary-care-experience
Zorgania AE, Piriea FJ, Motalaa AA. Characteristics and outcome of patients with pheochromocytoma at a tertiary endocrinology clinic in Durban, South Africa over 14 years. J Endocrinol Metab Diabetes South Africa [Internet]. 2018;23(2):52–8. DOI: from: http://doi.org/10.1080/16089677.2018.1446592
Alguire C, Chbat J, Forest I. Godbout A, Bourdeau I. Unusual presentation of pheochromocytoma: thirteen years of anxiety requiring psychiatric treatment. Endocrinol Diabetes Metab Case Reports. 2018;2018(April):1–5.
Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. In: Lancet. Elsevier; 2005 Vol 366 (9486). p. 665–75. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67139-5/fulltext
Rodrigues K, Toledo R, Coutinho F, Nunes A. Assessment of depression, anxiety, quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients. Thyroid. 2017;27(5):693–706. Available from: https://www.liebertpub.com/doi/abs/10.1089/thy.2016.0148?src=recsys&journalCode=thy
Cerqueira A, Seco T, Costa A, Tavares M, Cotter J. Pheochromocytoma and Paraganglioma: A Review of Diagnosis, Management and Treatment of Rare Causes of Hypertension. Cureus. 2020;12(5): e7969. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273359/
Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul. 2019;53(3):191–212. Available: https://pubmed.ncbi.nlm.nih.gov/31517632/
Pogorzelski R, Toutounchi S, Krajewska. The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent Eur J Urol. 2014;67(4):361–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310896/
Neumann H, Young WF, Krauss T, et al. 65 Years of the double helix Genetics informs precision practice in the diagnosis and management of pheochromocytoma. 2018;25(8). https://pubmed.ncbi.nlm.nih.gov/29794110/
Stolk RF, Bakx C, Mulder J, Timmers HJLM, Lenders JWM. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab. 2013;98(3):1100–6. Available from: https://pubmed.ncbi.nlm.nih.gov/23408574/
Greenleaf CE, Griffin LA, Shake JG, Orr WS. Hypertensive Crisis Secondary to Pheochromocytoma. Baylor Univ Med Cent Proc. 2017;30(3):314–5. Available from: https://pubmed.ncbi.nlm.nih.gov/28670069/
Soltani A, Pourian M, Davani BM. Does this patient have Pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord [Internet]. 2016;15(6):1–12. Available from: https://link.springer.com/content/pdf/10.1186/s40200-016-0226-x.pdf
Jóźwik-Plebanek K, Klisiewicz A, Januszewicz A, Prejbisz A. Transient dynamic left ventricular outflow tract obstruction in a patient with pheochromocytoma. Kardiol Pol. 2014;72(5):472. Available from: https://journals.viamedica.pl/kardiologia_polska/article/view/KP.2014.0101
Y-Hassan S, Falhammar H. Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas. J Clin Med. 2020;9(8):2435. Available from: https://pubmed.ncbi.nlm.nih.gov/32751501/
Falhammar H, Kjellman M, Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine [Internet]. 2018;62(3):566–75. Available from: http://dx.doi.org/10.1007/s12020-018-1734-x
Weismann D, Liu D, Bergen T, Peitzsch M, Raida A, Wagner M, et al. Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of phaeochromocytoma. Clin Endocrinol (Oxf). 2015;82(2):188–96. Available from: https://pubmed.ncbi.nlm.nih.gov/25040503/
Meijs AC, Snel M, Corssmit EPM. Pheochromocytoma/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas. Hormones. (Athens). 2021 Jun; 20 (2): 395-403. Avalaible from: https://pubmed.ncbi.nlm.nih.gov/33575936/
Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab. 2013;98(2):581–91. Available from: https://pubmed.ncbi.nlm.nih.gov/23284003/
Whitelaw BC, Prague JK, Mustafa OG. Phaeochromcytoma crisis. Clin Endocrinol (Oxf). 2014;80(1):13–22. Available from: https://pubmed.ncbi.nlm.nih.gov/24102156/
Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, et al. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol. 2015;173(6):757–64. Available from: https://pubmed.ncbi.nlm.nih.gov/26346138/
Tschuor C, Sadri H, Clavien PA. Pheochromocytoma crisis. Clin Case Reports. 2013;2(1):14. Available from: https://europepmc.org/article/MED/25356229
Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, Gilbert JA, et al. Phaeochromcytoma crisis. Clin Endocrinol (Oxf). 2014;80(1):13–22. Available from: https://pubmed.ncbi.nlm.nih.gov/24102156/
Nazari MA, Rosenblum JS, Haigney MC, Rosing DR, Pacak K. Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76(4):451–64. Available from: https://pubmed.ncbi.nlm.nih.gov/32703516/
Eschenhagen T. Treatment of hypertension. In: Brunton LL, Hilal-Dandan R KB, Editors., editors. The Pharmacological Basis of Therapeutics. McGrawHill. New York; 2018. Available from: https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189§ionid=170270855
Ortiz Vazquez I, Ramos M. Infarto agudo de miocardio relacionado con feocromocitoma. Rev Medica del Inst Mex del Seguro Soc. 2012;50(5):559–63. Available from: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=38747
Santos JRU, Brofferio A, Viana B, Pacak K. Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: ¿How to Manage a Rare Complication in a Rare Disease? Horm Metab Res. 2019;51(7):458–69. Available from: https://pubmed.ncbi.nlm.nih.gov/30227459/
Melson E, Amir S, Shepherd L, Kauser S, Freestone B, Kempegowda P. Myocardial infarction with non-obstructed coronaries – atypical presentation of pheochromocytoma. Endocrinol Diabetes Metab Case Reports. 2019; Oct 19; EDM 190089. Available from: https://pubmed.ncbi.nlm.nih.gov/31634865/
Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. Int J Cardiol [Internet]. 2017; 249:319–23. Available from: https://pubmed.ncbi.nlm.nih.gov/29121733/
Y-Hassan S, Falhammar H. Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered Takotsubo syndrome: A systematic review and meta-analysis of 156 published cases. Clin Cardiol. 2020;43(5):459–67. Available from: https://pubmed.ncbi.nlm.nih.gov/32125009/
Giavarini A, Chedid A, Bobrie G, Plouin PF, Hagège A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013;99(19):1438–44. Available from: https://pubmed.ncbi.nlm.nih.gov/23837998/
Y-Hassan S, Falhammar H. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome. Endocrine [Internet]. 2019;65(3):483–93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717601/
Patrova J, Jarocka I, Wahrenberg H, Falhammar H. Clinical Outcomes in Adrenal Incidentaloma: Experience From One Center. Endocr Pract. 2015;21(8):870–7. Available from: https://pubmed.ncbi.nlm.nih.gov/26121453/
Gardner DG et al. Greenspan Endocrinologia básica y clínica. Greenspan. Endocrinología básica y clínica. 2012. 878 p. ISBN 13: 978-1-4562-6264-8
Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am [Internet]. 2019;48(4):727–50. Available from: https://pubmed.ncbi.nlm.nih.gov/31655773/
Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. Available from: https://academic.oup.com/jcem/article/99/6/1915/2537399
Aygun N. Pheochromocytoma and paraganglioma: from clinical findings to diagnosis. SiSli Etfal Hastan Tip Bul / Med Bull Sisli Hosp. 2020;54(3):271–80. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729715/
Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. Clin Chem. 2018;64(11):1646–56. Available from: https://academic.oup.com/clinchem/article/64/11/1646/5608639
Därr R, Kuhn M. Accuracy of recommended sampling and assay methods for the determination of plasma free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: A systematic review. 2018;56(3):495–503. Available from: https://pubmed.ncbi.nlm.nih.gov/28405881/
Renard J, Clerici T, Licker M, Triponez F. Pheochromocytoma and abdominal paraganglioma. J Visc Surg [Internet]. 2011;148(6): e409–16. Available from: https://www.sciencedirect.com/science/article/pii/S1878788611000749?via%3Dihub
Antonio K, Noreen Valdez MM, Pacak K. Pheochromocytoma/paraganglioma: Recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020;9(1):105–23. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082276/
Salazar-vega JL, Solis Paola. Multiple Endocrine Neoplasia Type 2B (MEN2B) delayed diagnosis: importance of opportune recognition of MEN2 Syndromes in pediatric thyroid cancer. 2019; 56(1): 24–30. Available from:https://www.raem.org.ar/numeros/2019-vol56/numero-01/raem-56-01-24-29.pdf
Berends A, Kerstens M, Jacques P. Approach to the patient: Perioperative management of the patient with pheochromocytoma or sympathetic paraganglioma. J Clin Endocrinol Metab ,. 2020;105(9):3088–3102. Available from:https://pubmed.ncbi.nlm.nih.gov/32726444/
Bausch B, Tischler AS, Schmid KW, Leijon H, Eng C, Neumann HPH. MaxSchottelius: Pioneer in pheochromocytoma. J Endocr Soc. 2017;1(7):957–64. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689150/
Ma W, Mao Y, Zhuo R, Dai J, Fang C, Wang C, et al. Surgical outcomes of a randomized controlled trial compared robotic versus laparoscopic adrenalectomy for pheochromocytoma. Eur J Surg Oncol [Internet]. 2020;46(10):1843–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32723609/
Joynt KE, Moslehi JJ, Baughman KL. Paragangliomas: Etiology, presentation, and management. Cardiol Rev. 2009;17(4):159–64. Available from: https://pubmed.ncbi.nlm.nih.gov/19525677/
Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol. 2020;21(11): 85. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456409/ .
Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK V., Dahia PL, De Krijger RR, et al. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer. 2004;11(3):423–36. Available from: https://pubmed.ncbi.nlm.nih.gov/15369446/
Lenders JWM. Biochemical diagnosis of pheochromocytoma and paraganglioma. Ann Endocrinol (Paris). 2009;70(3):161–5. Available from:https://pubmed.ncbi.nlm.nih.gov/19296926/
Los autores que publiquen en esta revista aceptan las siguientes condiciones:
1. Los autores conservan los derechos de autor y ceden a la REVISTA MÉDICA - CIENTÍFICA CAMbios HCAM el derecho de la primera publicación, con el trabajo registrado con la licencia de atribución de Creative Commons, que permite a terceros utilizar lo publicado siempre que mencionen la autoría del trabajo y a la primera publicación en esta revista.
2. Los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en la REVISTA MÉDICA-CIENTÍFICA CAMbios HECAM.
1.jpg)